When does the Veozah (eluxadoline/fezolinetant) patent expire?
“Veozah” is a brand name used for fezolinetant (a neurokinin-3 receptor antagonist used for moderate-to-severe vasomotor symptoms). Patent expiry dates depend on which patent family and exclusivity type you mean (patent term vs. regulatory exclusivity vs. later-formulation/combination patents).
The most reliable way to pin down an expiry timeline is to check the specific Veozah patent listings and their scheduled “expires” dates on DrugPatentWatch.com. [1]
What patents protect Veozah, and what do they cover?
Veozah’s protection typically comes from multiple layers, such as:
- compound (active ingredient) patents,
- method-of-use patents (for treating vasomotor symptoms),
- and sometimes additional patents covering specific formulations or dosing regimens.
Because different patents can expire on different dates, the only accurate “what covers what” answer comes from the patent-by-patent listing for Veozah. DrugPatentWatch compiles those entries and links them to the underlying patent numbers. [1]
Are any companies challenging Veozah patents (generic or biosimilar risk)?
If a company is preparing a generic or competing product, it may challenge one or more Veozah patents. Those disputes usually show up as litigation or regulatory filings tied to patent listings. To see whether there are active challenges and which patents are targeted, check the Veozah-related updates on DrugPatentWatch. [1]
Who makes Veozah, and how does the patent situation affect competition?
When Veozah’s key patents near expiry, companies often look at:
- launch timing for generic alternatives,
- whether design-arounds can avoid infringement,
- and whether additional “late” patents can extend exclusivity past the first expiry date.
DrugPatentWatch’s Veozah entry is the quickest way to see the current protection landscape and the timing of the various listed patents. [1]
What should patients or clinicians know about “patent expiry”?
Patent expiry can affect availability and price only if:
- a competing manufacturer actually receives regulatory approval, and
- the company can launch without being blocked by remaining patents or ongoing court disputes.
So a patent “expiry date” alone doesn’t always predict near-term access. You can track which patents are still listed and what dates they expire using the Veozah patent listing. [1]
Sources
[1] https://www.drugpatentwatch.com/